Welcome!

News Feed Item

Milestone Scientific Reports Fourth Quarter and 2013 Financial Results

Revenue Increases 15.8% to $10.0 Million in 2013; Domestic Instrument Sales Increase 44.8%; Achieves Net Income of $1.5 Million in 2013; Shareholders' Equity Increases to $5.5 Million at the End of Fiscal 2013 Compared to $1.9 Million at the End

LIVINGSTON, NJ--(Marketwired - March 12, 2014) - Milestone Scientific Inc. (OTCQB: MLSS), a leading medical research and development company that designs and patents innovative injection technology, today announced financial results for the fourth quarter and year ended December 31, 2013.

2013 Operating Highlights:

  • Formed a strategic partnership with Tri-anim Health Services Inc., a division of Sarnova Inc., one of the nation's largest specialty distributors of healthcare products, to distribute Milestone Medical's epidural instrument
  • Listed Milestone Medical subsidiary on the Warsaw Stock Exchange and raised $3 million from European investors
  • Implemented the use of the Wand® STA instrument in additional college and university dental hygienist programs

Leonard Osser, Chief Executive Officer of Milestone Scientific stated, "We are pleased to report positive financial results for the year ended December 31, 2013. We continue to see top and bottom line growth, with revenue increasing 15.8% to $10.0 million and net income increasing to $1.5 million for 2013, compared to a net loss of approximately ($870,306) in 2012. Notably, we achieved a 44.8% increase in domestic instrument sales to $1.2 million in 2013. At the same time, our balance sheet continues to improve as we increased shareholders' equity to $5.5 million as of December 31, 2013. The improvement in shareholders' equity was principally attributable to the increase in net income, conversion of a long term note, and a small private placement in 2013."

"We continue to maintain a successful distribution relationship with Aseptico, which provides us greater transparency with our customers. As a result, we are able to establish a direct relationship with dentists and provide them with a training program through our in-house education staff as well as our hygienists in the field to make an effort to have them use the instrument to the fullest capacity. Due to certain sales incentives and arrangements with our distributors, we anticipate lower handpiece sales in the first quarter and second quarter of 2014 as compared to the fourth quarter of 2013. However, we expect to more than make up for this decline in the second half of 2014 since we know from experience that once we train dentists, they utilize a greater number of handpieces each year. We are also implementing promotions and incentives on the Wand® STA instruments in 2014 to our distributors worldwide which should increase instrument sales. The increase in instrument sales will help drive handpiece sales beginning in the second half of 2014, which will result in increased sales and increased bottom line but lower margins.

"In 2013, we announced a strategic partnership with Tri-anim Health Services Inc., one of the nation's largest specialty distributors of healthcare products. Upon FDA approval, Tri-anim will be the exclusive distributer of Milestone Medical's epidural instrument. Tri-anim is one of the largest distributors to birthing hospitals across the U.S., and is an important validation of the market potential for our instruments."

"Lastly, our subsidiary, Milestone Medical Inc., recently listed on the Warsaw Stock Exchange. The listing followed a $3 million raise from European investors. The money we raised in Poland will help us accelerate the launch of our first two medical instruments, epidural and intra-articular, which are based on our patented Dynamic Pressure Sensing® system. We believe these first two medical instruments represent a significant market opportunity for both Milestone Medical Inc. and Milestone Scientific Inc. We look forward to introducing additional instruments serving a wide array of medical applications, and believe this recent funding demonstrates our ability to cost-effectively bring new instruments to market, while minimizing dilution to shareholders."

Revenue for the three months ended December 31, 2013 increased 23.3% to $2.8 million versus $2.3 million for the fourth quarter of 2012. Domestic instrument sales increased by 30.9% to $378,801 in the fourth quarter of 2013 versus the same quarter in 2012 due to the increased demand at the distributor and group dental practice levels. In the domestic market, handpiece sales increased by $211,547 or 27.3%. On the international front, total revenue was $1,407,455, a 18.9% increase versus the same period in 2012. International handpiece sales increased by $166,973 or 20.6% in the fourth quarter of 2013 versus 2012. Gross profit for the fourth quarter of 2013 was $1.8 million or 65.5% of revenue versus $1.4 million or 59.8% of revenue in the fourth quarter of 2012. Net income for the fourth quarter of 2013 was $1.0 million, or $0.05 per diluted share, versus net loss of ($365,735), or ($0.02) per diluted share for the comparable period in 2012. 

Revenue for the year ended December 31, 2013 increased 15.8% to $10.0 million versus $8.6 million for the year ended 2012. The increase in product sales of $1,363,178 was primarily the result of increased domestic revenue. Domestic instrument sales increased by $377,752 or 44.8% in 2013 versus 2012 due to increased demand at the distributor and group dental practice levels. In the domestic market, handpiece sales increased by $561,355 or 16.5%. International instrument sales increased by $147,517 or 11.3% in 2013 versus 2012. In the international market, handpiece sales increased by $389,434 or 13.2%. Gross profit for 2013 was $6.8 million or 68.0% of revenue versus $5.6 million or 64.7% of revenue in 2012. Operating income for 2013 was $1.1 million versus operating loss of ($520,353) for 2012. Net income for 2013 was $1.5 million or $0.08 per diluted share, versus net loss of ($870,306), or ($0.05) per diluted share in 2012. The increase in net income is attributable to an increase in sales and gross margin dollars, as well as a significant decrease in selling, general and administrative expenses and the net positive impact of Milestone Medical Inc. (joint venture). 

Milestone's executive management team will host a teleconference on Thursday, March 13th at 8:30am Eastern Daylight Time to discuss the company's financial results. The conference call can be accessed via telephone by dialing toll free 1-877-941-9205. For those unable to participate at that time, a replay of the call can be accessed by dialing 1-800-406-7325 and entering the pass code 4673676. The replay will be available for 90 days.

About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com

Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2013. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

                                                                            
                                                                            
                         MILESTONE SCIENTIFIC INC.                          
                     CONDENSED STATEMENTS OF OPERATIONS                     
                                (Unaudited)                                 
                                                                            
                                                                            
                                                                            
                                             December 31,     December 31,  
                                                 2013             2012      
                                           ---------------  --------------- 
Product sales, net                         $    10,011,420  $     8,648,242 
Cost of products sold                            3,198,908        3,055,991 
                                           ---------------  --------------- 
Gross profit                                     6,812,512        5,592,251 
                                           ---------------  --------------- 
Selling, general and administrative                                         
 expenses                                        5,534,463        5,930,625 
Research and development expenses                  191,345          181,979 
                                           ---------------  --------------- 
  Total operating expenses                       5,725,808        6,112,604 
                                           ---------------  --------------- 
    Income (loss) from operations                1,086,704         (520,353)
Other income (expense)                                                      
  Other income                                      17,543                - 
  Interest income                                      115               34 
  Interest expense                                 (70,801)        (175,905)
  Interest-Amortized debt issuance - cost                -           (3,065)
  Loss on Earnings from Medical Joint                                       
   Venture                                        (924,363)        (171,016)
  Loss on Earnings from Education Joint                                     
   Venture                                          (7,918)               - 
  Gain on dilutive effect on Medical Joint                                  
   Venture stock issuance                        1,363,650                - 
                                           ---------------  --------------- 
    Total other expense, net                       378,226         (349,952)
                                           ---------------  --------------- 
      Income (loss)                              1,464,930         (870,306)
                                           ---------------  --------------- 
Provision for Income Tax                                 -                - 
                                           ---------------  --------------- 
      Net income (loss)                    $     1,464,930  $      (870,306)
                                           ===============  =============== 
Net income (loss) per share applicable to                                   
 common stockholders -                                                      
  Basic                                    $          0.09  $         (0.05)
                                           ===============  =============== 
  Diluted                                  $          0.08  $         (0.05)
                                           ===============  =============== 
Weighted average shares outstanding and to                                  
 be issued -                                                                
  Basic                                         17,127,468       16,080,474 
                                           ===============  =============== 
  Diluted                                       17,483,638       16,080,474 
                                           ===============  =============== 
                                                                            
                                                                            
                                                                            
                          MILESTONE SCIENTIFIC INC.                         
                          CONDENSED BALANCE SHEETS                          
                                                                            
                                                                            
                                                                            
                                       December 31, 2013  December 31, 2012 
                                       -----------------  ----------------- 
                                                                            
                ASSETS                                                      
Current Assets:                                                             
  Cash and cash equivalents            $       1,147,198  $         165,249 
  Accounts receivable, net of                                               
   allowance for doubtful accounts of                                       
   $5,000 in 2013 and $179,259 in 2012         1,532,856            978,982 
  Inventories                                  1,321,652            638,561 
  Advances on contracts                          727,478            476,969 
  Prepaid expenses and other current                                        
   assets                                        150,451            239,061 
                                       -----------------  ----------------- 
    Total current assets                       4,879,635          2,498,822 
Accounts receivable-long term, net of                                       
 allowance for doubtful accounts                                            
of $167,971 in 2012                                    -            119,201 
Advances on contracts                          1,580,874          2,350,477 
Investment in Milestone Medical Inc              924,115                  - 
Investment in Milestone Education LLC             42,082                  - 
Furniture, Fixtures & Equipment net of                                      
 accumulated depreciation of                                                
 $476,884as of December 31, 2013 and              23,988             36,624 
 $458,708 as of December 31, 2012                                           
Patents, net of accumulated                                                 
 amortization of $498,502 as of                                             
 December 31, 2013 and $420,556 as of                                       
 December 31, 2012                               591,735            648,662 
Other assets                                      12,917              7,317 
                                       -----------------  ----------------- 
      Total assets                     $       8,055,346  $       5,661,103 
                                       =================  ================= 
                                                                            
 LIABILITIES AND STOCKHOLDERS' EQUITY                                       
Current Liabilities:                                                        
  Accounts payable                     $       2,020,368  $       2,336,594 
  Accrued expenses and other payable             515,132            581,407 
  Accrued interest on Notes Payable                    -            356,563 
                                       -----------------  ----------------- 
    Total current liabilities                  2,535,500          3,274,564 
                                       -----------------  ----------------- 
                                                                            
Long-term Liabilities:                                                      
  Notes payable                                        -            450,000 
                                       -----------------  ----------------- 
    Total long-term liabilities                        -            450,000 
                                       -----------------  ----------------- 
                                                                            
Commitments and Contingencies                                               
                                                                            
Stockholders' Equity                                                        
  Preferred Stock, par value $.001,                                         
   5,000,000 shares                                    -                  - 
  Common stock, par value $.001;                                            
   authorized 50,000,000 shares;                                            
   17,759,540 shares issued 1,839,930                                       
   shares to be issued and 17,726,207                                       
   shares outstanding as of December                                        
   31, 2013; 16,563,306 shares issued                                       
   1,635,709 shares to be issued and                                        
   16,529,973 shares out                          19,599             18,199 
  Additional paid-in capital                  66,677,200         64,560,224 
  Accumulated deficit                        (60,265,438)       (61,730,368)
  Treasury stock, at cost, 33,333                                           
   shares                                       (911,516)          (911,516)
                                       -----------------  ----------------- 
    Total stockholders' equity                 5,519,846          1,936,539 
                                       -----------------  ----------------- 
      Total liabilities and                                                 
       stockholders' equity            $       8,055,346  $       5,661,103 
                                       -----------------  ----------------- 
                                                                            
                                                                            
                                                                            

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Eighty percent of a data scientist’s time is spent gathering and cleaning up data, and 80% of all data is unstructured and almost never analyzed. Cognitive computing, in combination with Big Data, is changing the equation by creating data reservoirs and using natural language processing to enable analysis of unstructured data sources. This is impacting every aspect of the analytics profession from how data is mined (and by whom) to how it is delivered. This is not some futuristic vision: it's ha...
Let’s face it, embracing new storage technologies, capabilities and upgrading to new hardware often adds complexity and increases costs. In his session at 18th Cloud Expo, Seth Oxenhorn, Vice President of Business Development & Alliances at FalconStor, will discuss how a truly heterogeneous software-defined storage approach can add value to legacy platforms and heterogeneous environments. The result reduces complexity, significantly lowers cost, and provides IT organizations with improved effi...
Data-as-a-Service is the complete package for the transformation of raw data into meaningful data assets and the delivery of those data assets. In her session at 18th Cloud Expo, Lakshmi Randall, an industry expert, analyst and strategist, will address: What is DaaS (Data-as-a-Service)? Challenges addressed by DaaS Vendors that are enabling DaaS Architecture options for DaaS
With the Apple Watch making its way onto wrists all over the world, it’s only a matter of time before it becomes a staple in the workplace. In fact, Forrester reported that 68 percent of technology and business decision-makers characterize wearables as a top priority for 2015. Recognizing their business value early on, FinancialForce.com was the first to bring ERP to wearables, helping streamline communication across front and back office functions. In his session at @ThingsExpo, Kevin Roberts...
One of the bewildering things about DevOps is integrating the massive toolchain including the dozens of new tools that seem to crop up every year. Part of DevOps is Continuous Delivery and having a complex toolchain can add additional integration and setup to your developer environment. In his session at @DevOpsSummit at 18th Cloud Expo, Miko Matsumura, Chief Marketing Officer of Gradle Inc., will discuss which tools to use in a developer stack, how to provision the toolchain to minimize onboa...
Cognitive Computing is becoming the foundation for a new generation of solutions that have the potential to transform business. Unlike traditional approaches to building solutions, a cognitive computing approach allows the data to help determine the way applications are designed. This contrasts with conventional software development that begins with defining logic based on the current way a business operates. In her session at 18th Cloud Expo, Judith S. Hurwitz, President and CEO of Hurwitz & ...
It's easy to assume that your app will run on a fast and reliable network. The reality for your app's users, though, is often a slow, unreliable network with spotty coverage. What happens when the network doesn't work, or when the device is in airplane mode? You get unhappy, frustrated users. An offline-first app is an app that works, without error, when there is no network connection.
The principles behind DevOps are not new - for decades people have been automating system administration and decreasing the time to deploy apps and perform other management tasks. However, only recently did we see the tools and the will necessary to share the benefits and power of automation with a wider circle of people. In his session at DevOps Summit, Bernard Sanders, Chief Technology Officer at CloudBolt Software, explored the latest tools including Puppet, Chef, Docker, and CMPs needed to...
The cloud promises new levels of agility and cost-savings for Big Data, data warehousing and analytics. But it’s challenging to understand all the options – from IaaS and PaaS to newer services like HaaS (Hadoop as a Service) and BDaaS (Big Data as a Service). In her session at @BigDataExpo at @ThingsExpo, Hannah Smalltree, a director at Cazena, will provide an educational overview of emerging “as-a-service” options for Big Data in the cloud. This is critical background for IT and data profes...
Father business cycles and digital consumers are forcing enterprises to respond faster to customer needs and competitive demands. Successful integration of DevOps and Agile development will be key for business success in today’s digital economy. In his session at DevOps Summit, Pradeep Prabhu, Co-Founder & CEO of Cloudmunch, covered the critical practices that enterprises should consider to seamlessly integrate Agile and DevOps processes, barriers to implementing this in the enterprise, and pr...
SYS-CON Events announced today that Men & Mice, the leading global provider of DNS, DHCP and IP address management overlay solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. The Men & Mice Suite overlay solution is already known for its powerful application in heterogeneous operating environments, enabling enterprises to scale without fuss. Building on a solid range of diverse platform support,...
Advances in technology and ubiquitous connectivity have made the utilization of a dispersed workforce more common. Whether that remote team is located across the street or country, management styles/ approaches will have to be adjusted to accommodate this new dynamic. In his session at 17th Cloud Expo, Sagi Brody, Chief Technology Officer at Webair Internet Development Inc., focused on the challenges of managing remote teams, providing real-world examples that demonstrate what works and what do...
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
As enterprises work to take advantage of Big Data technologies, they frequently become distracted by product-level decisions. In most new Big Data builds this approach is completely counter-productive: it presupposes tools that may not be a fit for development teams, forces IT to take on the burden of evaluating and maintaining unfamiliar technology, and represents a major up-front expense. In his session at @BigDataExpo at @ThingsExpo, Andrew Warfield, CTO and Co-Founder of Coho Data, will dis...
In most cases, it is convenient to have some human interaction with a web (micro-)service, no matter how small it is. A traditional approach would be to create an HTTP interface, where user requests will be dispatched and HTML/CSS pages must be served. This approach is indeed very traditional for a web site, but not really convenient for a web service, which is not intended to be good looking, 24x7 up and running and UX-optimized. Instead, talking to a web service in a chat-bot mode would be muc...